Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NRAS Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT07777822
What this trial is testing

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Who this might be right for
NSCLCNon-small Cell Lung CancerNon-Small Cell Lung Cancer NSCLC+4 more
Revolution Medicines, Inc. 430
Not applicableStudy completedNCT01543113
What this trial is testing

CKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project

Who this might be right for
Melanoma
Rennes University Hospital 288
Testing effectiveness (Phase 2)Looking for participantsNCT05786924
What this trial is testing

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Who this might be right for
Non-small Cell Lung CancerHistiocytic NeoplasmHistiocytosis+29 more
Institut de Recherches Internationales Servier 554
Early research (Phase 1)Not Yet RecruitingNCT07014878
What this trial is testing

DCTY1102 Injection in Participants With Advanced Solid Tumors

Who this might be right for
Colorectal CancerLung CancerPancreatic Cancer
Beijing DCTY Biotech Co.,Ltd. 18
Early research (Phase 1)Study completedNCT01225536
What this trial is testing

Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations

Who this might be right for
Solid Tumor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) 24
Testing effectiveness (Phase 2)Study completedNCT01704703
What this trial is testing

Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques

Who this might be right for
Stage IV Colorectal Cancer
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 72
Testing effectiveness (Phase 2)Looking for participantsNCT05841550
What this trial is testing

The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma

Who this might be right for
Multiple MyelomaSmoldering Multiple Myeloma
Oslo University Hospital 20
Testing effectiveness (Phase 2)Study completedNCT05039177
What this trial is testing

ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

Who this might be right for
Metastatic Colorectal CancerMetastatic Pancreatic Ductal Adenocarcinoma
Erasca, Inc. 101
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945
What this trial is testing

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more
Academic and Community Cancer Research United 22
Large-scale testing (Phase 3)Active Not RecruitingNCT06625320
What this trial is testing

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Looking for participantsNCT07397338
What this trial is testing

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Solid TumorsNon-small Cell Lung Cancer (NSCLC)+3 more
Revolution Medicines, Inc. 370
Testing effectiveness (Phase 2)Active Not RecruitingNCT06106308
What this trial is testing

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Who this might be right for
Metastatic Colorectal CancerCRCKRAS/NRAS Mutation
Cardiff Oncology 110
Early research (Phase 1)Study completedNCT05187858
What this trial is testing

LNP3794 in Subjects With NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors

Who this might be right for
NRAS/KRAS Mutated Advanced or Metastatic Refractory Solid Tumors
Lupin Ltd. 15
Large-scale testing (Phase 3)Looking for participantsNCT06881784
What this trial is testing

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Non-Small Cell Lung CancerNSCLC+2 more
Revolution Medicines, Inc. 590
Testing effectiveness (Phase 2)Looking for participantsNCT06229340
What this trial is testing

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations

Who this might be right for
RAS MutationRas (Kras or Nras) Gene MutationColorectal Cancer Recurrent+4 more
N.N. Petrov National Medical Research Center of Oncology 20
Early research (Phase 1)Temporarily pausedNCT04418167
What this trial is testing

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

Who this might be right for
Solid Tumors
JS InnoPharm, LLC 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439344
What this trial is testing

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 53
Not applicableStudy completedNCT03750175
What this trial is testing

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

Who this might be right for
Colorectal Cancer MetastaticCirculating Tumor DNAKRAS Gene Mutation+3 more
Karen-Lise Garm Spindler 49
Testing effectiveness (Phase 2)Study completedNCT01362296
What this trial is testing

An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer, Non-Small Cell
GlaxoSmithKline 134
Early research (Phase 1)Ended earlyNCT04249843
What this trial is testing

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Who this might be right for
Solid TumorB-Raf Mutation-Related Tumors
MapKure, LLC 109
Next Page